

Chapter 10. Musculoskeletal and joint diseases







Contents

[10.1 Drugs used in rheumatic diseases and gout](#)

[10.2 Drugs used in neuromuscular disorders](#)

[10.3 Drugs for the relief of soft-tissue inflammation](#)

Key

	<p>Red drug see GMMMG RAG list <i>Click on the symbols to access this list</i></p>
	<p>Amber drug see GMMMG RAG list <i>Click on the symbols to access this list</i></p>
	<p>Green drug see GMMMG RAG list <i>Click on the symbols to access this list</i></p>
	<p>If a medicine is unlicensed this should be highlighted in the template as follows Drug name U</p>
	<p>Not Recommended</p>
	<p>Over the Counter In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care. For further details see GM commissioning statement.</p>
<p>Order of Drug Choice</p>	<p>Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order.</p>

BNF chapter	10	Musculoskeletal and joint diseases
Section	10.1	Drugs used in rheumatic diseases and gout
Subsection	10.1.1	Non-steroidal anti-inflammatory drugs
First choice	Ibuprofen tablets 200mg; 400mg; 600mg	MHRA DSU: High-dose ibuprofen: small increase in cardiovascular risk, June 2015
Alternatives	Naproxen tablets 250mg; 500mg	
	Diclofenac tablets 50mg	MHRA DSU: diclofenac: new contraindications and warnings, June 2013. MHRA DSU: NSAIDs: cardiovascular risks October 2012. Further evidence that the cardiovascular risk with diclofenac is higher than other non-selective NSAIDs and similar to the selective COX-2 inhibitors
	Etoricoxib tablets 30mg, 60mg, 90mg, 120mg	MHRA DSU: Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis MHRA DSU: etoricoxib: prescribing to patients with high blood pressure, July 2008.
Grey drugs Items which are listed as Grey are deemed not suitable for routine prescribing but may be suitable for a defined patient population	Piroxicam Capsules, orodispersible tablets Systemic piroxicam should be initiated only by specialists as a second-line treatment for arthritis. Patients who currently take piroxicam should be reassessed at a routine appointment.	G_n following specialist initiation Criterion 1 (see RAG list)
	Celecoxib Capsules Only for use in palliative care for the relief of cancer pain.	G_n Criterion 1 (see RAG list)
Do Not Prescribe	Naproxen with esomeprazole Modified-release tablets	Criterion 2 (see RAG list)

General Guidance applicable to all drugs

- [NICE NG226: Osteoarthritis in over 16s: diagnosis and management.](#)
- [NICE NG100: Rheumatoid arthritis in adults: management.](#)
- [CKS \(2013\) NSAID prescribing issues](#)
- [BNF: NSAID-associated ulcers](#)
- [CKS \(2013\): Patients on low dose aspirin](#)
- [MHRA DSU: Non-steroidal anti-inflammatory drugs: reminder on renal failure and impairment, May 2009](#)
- [MHRA DSU: Non-steroidal anti-inflammatory drugs: cardiovascular risk, October 2012](#)
- [MHRA DSU: NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks, December 2007](#)

Subsection	10.1.2 Corticosteroids
-------------------	-------------------------------

Systemic corticosteroids

The general actions, uses, and cautions of corticosteroids are described [in the BNF](#).

Local corticosteroid injections

First choice	Methylprednisolone acetate 40mg/ml or Methylprednisolone acetate 40mg, lidocaine hydrochloride 10mg/ml	
Alternatives	Dexamethasone sodium phosphate 3.8mg/ml	MHRA DSU: Dexamethasone 4 mg/ml injection (Organon Laboratories Limited): reformulation with changes in name, concentration, storage conditions, and presentation, October 2014.
	Hydrocortisone acetate 25mg/ml	
	Triamcinolone acetonide 10mg/ml Triamcinolone acetonide 40mg/ml	

	<p>Mycophenolate U Tablets 500mg, Capsules 250mg</p>	<p>A</p> <p>MHRA DSU: Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men 2015</p> <p>MHRA DSU: Mycophenolate mofetil: pure red cell aplasia, July 2009</p> <p>MHRA DSU: Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis, January 2015</p>
<p>General guidance applicable to all drugs</p> <ul style="list-style-type: none"> NICE NG100: Rheumatoid arthritis in adults: management. 		
<p>Biologics (secondary care use only)</p>		
<p>See also GMMMG High Cost Drugs Pathways for:</p> <ul style="list-style-type: none"> Rheumatoid Arthritis Ankylosing spondylitis Psoriatic arthritis 		
<p>First Choices (Follow relevant pathway)</p>	<p>Abatacept Injection or infusion</p>	<p>R Prevents full activation of T-lymphocytes</p> <p>TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor.</p> <p>TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed</p> <p>TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed</p>
	<p>Adalimumab First choice: Amgevita® ▼ Alternative: Humira® Solution for injection</p>	<p>R TNF inhibitor</p> <p>TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor.</p> <p>TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis</p> <p>TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed</p> <p>TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis</p> <p>TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa</p>

		TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Apremilast (Otezla®) Tablets	R PDE4 Inhibitor	TA433: Apremilast for treating active psoriatic arthritis MHRA: Apremilast (Otezla ▼): risk of suicidal thoughts and behaviour
Baricitinib ▼ (Olumiant®) 2mg and 4mg tablets	R JAK inhibitor	TA466: Baricitinib for moderate to severe rheumatoid arthritis NICE NG191: COVID-19 rapid guideline: managing COVID-19 MHRA DSU: Baricitinib (Olumiant ▼): risk of venous thromboembolism, March 2020 MHRA DSU: Baricitinib (Olumiant ▼): increased risk of diverticulitis, particularly in patients with risk factors, Aug 2020 MHRA DSU: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality, April 2023
Belimumab ▼ Infusion	R Inhibits activity of B-lymphocyte stimulator	TA752: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Certolizumab pegol Solution for injection	R TNF inhibitor	TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Etanercept Solution for injection	R TNF inhibitor	TA35: Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed

<p>Filgotinib ▼ 100mg and 200 mg tablets</p>	<p>R JAK inhibitor TA676: Filgotinib for treating moderate to severe rheumatoid arthritis MHRA DSU: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality, April 2023</p>
<p>Golimumab Solution for injection</p>	<p>R TNF inhibitor TA220: Golimumab for the treatment of psoriatic arthritis. TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs. TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis TA497: Golimumab for treating non-radiographic axial spondyloarthritis</p>
<p>Guselkumab Solution for injection</p>	<p>R IL-23 inhibitor TA711: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs TA815: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs</p>
<p>Infliximab Infusion</p>	<p>R TNF inhibitor TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed</p>
<p>Ixekizumab Solution for injection</p>	<p>R Interleukin 17 antagonist TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs TA718: Ixekizumab for treating axial spondyloarthritis</p>

	<p>Risankizumab ▼ Solution for injection</p>	<p>R Interleukin 23 antagonist TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs</p>
	<p>Rituximab Infusion</p>	<p>R Anti-lymphocytic - causes lysis of B lymphocytes MHRA DSU: Rituximab: progressive multifocal leukoencephalopathy in a patient without prior treatment for rheumatoid arthritis, December 2009. MHRA DSU: Rituximab: screen for hepatitis B virus before treatment, December 2013 TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. GMMMG Rituximab biosimilar recommendation (August 2017)</p>
	<p>Sarilumab ▼ Solution for injection</p>	<p>R Interleukin-6 antagonist TA485: Sarilumab for moderate to severe rheumatoid arthritis NG191: managing COVID-19</p>
	<p>Secukinumab Solution for injection</p>	<p>R TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors TA719: Secukinumab for treating non-radiographic axial spondyloarthritis</p>
	<p>Tocilizumab Injection, infusion</p>	<p>R Interleukin-6 antagonist TA238: Systemic juvenile idiopathic arthritis – tocilizumab. TA247: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. TA518: Tocilizumab for treating giant cell arteritis NG191: managing COVID-19</p>
	<p>Tofacitinib ▼ 5mg and 10mg tablets</p>	<p>R JAK inhibitor TA480: Tofacitinib for moderate to severe rheumatoid arthritis TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs MHRA DSU: Tofacitinib (Xeljanz ▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections, March 2020 MHRA DSU: Tofacitinib (Xeljanz ▼): new measures to minimise risk of major adverse cardiovascular events and malignancies, Oct 2021</p>

		MHRA DSU: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality, April 2023
Upadacitinib ▼ Prolonged-release tablets	R JAK inhibitor	TA665: Upadacitinib for treating severe rheumatoid arthritis TA744: Upadacitinib for treating moderate rheumatoid arthritis TA768: for treating active psoriatic arthritis after inadequate response to DMARDs TA829: Upadacitinib for treating active ankylosing spondylitis MHRA DSU: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality, April 2023
Ustekinumab Solution for injection	R	TA340: Ustekinumab for treating active psoriatic arthritis.

General guidance applicable to all drugs

- Biologics in Rheumatoid Arthritis can be used, without prior funding approval, according to [GMMMG approved pathways](#): High Cost Drugs Pathway for Rheumatoid Arthritis, High Cost Drugs Pathway for Ankylosing Spondylitis, and High Cost Drugs Pathway for Psoriatic Arthritis
- [MHRA DSU: Tumour necrosis factor alpha inhibitors: risk of tuberculosis—screen all patients before starting treatment and monitor them closely, April 2014](#)
- [MHRA DSU: TNFa inhibitors: risk of TB – screen all patients before starting treatment and monitor them closely \(April 2016\)](#)

Additional NICE guidance and technology appraisals:

- [NICE NG100: Rheumatoid arthritis in adults: management.](#)
- [NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis](#)

Subsection

10.1.4 Gout and cytotoxic induced hyperuricaemia

General guidance applicable to all drugs

- [NICE NG219: Gout: diagnosis and management](#)
- [British Society for Rheumatology Guideline for the Management of Gout](#)

NICE Technology Appraisals:

- [NICE TA291: Pegloticase for treating severe debilitating chronic tophaceous gout](#)

Acute attack

First choice Alternative where NSAIDS contraindicated	Colchicine 500microgram tablets	MHRA DSU: colchicine: extremely toxic in overdose. November 2009.
---	--	---

Long-term control of gout		
First choice	Allopurinol tablets 100mg; 300mg	
Alternatives	Febuxostat tablets 80mg; 120mg	<p>G_n</p> <p>Use only where allopurinol is contraindicated or not tolerated. (As per NICE guidance and/or on specialist advice.)</p> <p>MHRA DSU: Febuxostat (Adenuric▼): stop treatment if signs or symptoms of serious hypersensitivity occur, June 2012.</p>
	Sulfinpyrazone tablets 100mg; 200mg	
Do Not Prescribe	Lesinurad Tablets	<u>Criterion 2 (see RAG list)</u>
Subsection	10.1.5 Other drugs for rheumatic diseases	
<p>Applicable guidance:</p> <ul style="list-style-type: none"> NICE NG226: Osteoarthritis in over 16s: diagnosis and management - section 1.4.6 Do not offer glucosamine products or strong opioids for the management of osteoarthritis. GMMMG 'Do Not Prescribe and Grey Lists': glucosamine and synovial fluid injections (including hyaluronan and sodium hyaluronate injection). GM Policy Statement (2020). Hyaluronic Acid injections for Osteoarthritis (GM037). <p>NICE Technology Appraisals:</p> <ul style="list-style-type: none"> NICE TA477: Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee NICE TA508: Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee 		
Do Not Prescribe	Glucosamine With or without chondroitin	<u>Criterion 1 (see RAG list)</u>
	Synovial fluid injections Including hyaluronan and sodium hyaluronate injections	<u>Criterion 1 (see RAG list)</u>

Section	10.2 Drugs used in neuromuscular disorders	
Subsection	10.2.1 Drugs that enhance neuromuscular transmission	
First choice	Pyridostigmine tablets: 60mg	
Alternatives	Neostigmine tablets: 15mg	
Subsection	10.2.2 Skeletal muscle relaxants	
First choice	Dantrolene capsules: 25mg, 100mg	
Alternatives	Diazepam tablets 2mg, 5mg, 10mg oral solution 2mg/5ml	
	Baclofen tablets: 10mg oral solution: 5mg/5ml	
	Mexiletine capsules: 167mg	R NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
	Tizanidine tablets: 2mg, 4mg	Gn Following specialist initiation
Section	Miscellaneous	
	Nusinersen (Prevymis®) tablets: 240mg	R NICE TA588: Nusinersen for treating spinal muscular atrophy
	Risdiplam (Evrysdi®▼) powder for oral solution 0.75mg/ml	R NICE TA755: Risdiplam for treating spinal muscular atrophy
Do Not Prescribe	Therabite® Jaw rehabilitation system	Criterion 1 (see RAG list)

Section	10.3 Drugs for the relief of soft-tissue inflammation	
Subsection	10.3.1 Enzymes (Secondary care use)	
	Collagenase (Xiapex®)	R NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren's contracture
Subsection	10.3.2 Rubefaciants and other topical antirheumatics	
Rubefaciants		
Do Not Prescribe	Rubefaciants Topical rubefacient products may contain nicotinate and salicylate compounds, essential oils, capsicum, and camphor. Topical NSAID or capsaicin preps are not rubefaciants	Criterion 1 (see RAG list)
Topical NSAIDS		
Options	Ibuprofen 5% Gel (Available as 30g, 50g or 100g tubes)	
	Ketoprofen 2.5% Gel (Available as 30g, 50g or 100g tubes)	MHRA DSU: topical ketoprofen: reminder on photosensitivity reactions, June 2009 and MHRA August 2010:
	Piroxicam 0.5% Gel (Available as 60g or 112g tubes)	
Capsaicin		
Options	Capsaicin 0.025% cream	NICE CG177: Osteoarthritis: Care and management in adults. GMMMG Neuropathic Pain Guideline November 2019
	Capsaicin 0.075% cream	
Poultices		
Not recommended for prescribing		